Bloqueadores ácidos competitivos de potasio (PCABs): estado del arte
DOI:
https://doi.org/10.47892/rgp.2025.451.1873Palabras clave:
Inhibidores de la Bomba de Protones, Determinación de la Acidez Gástrica, Revisión del Estado del ArteResumen
Los bloqueantes de ácidos competitivos de potasio (PCABs) constituyen una clase emergente de fármacos para el tratamiento de los trastornos relacionados con la acidez gástrica. Representan una alternativa a los inhibidores de la bomba de protones (IBPs), los cuales han sido el estándar terapéutico, pero presentan ciertas limitaciones. Los bloqueantes de ácidos competitivos de potasio (PCABs) presentan ventajas significativas sobre los inhibidores de la bomba de protones (IBP) en términos de rapidez de acción, potencia y duración de la supresión ácida, así como en la eficacia para el tratamiento de la esofagitis erosiva y la erradicación de Helicobacter pylori, entre otros aspectos. Además, muestran una menor variabilidad interindividual. Actualmente, los PCABs están disponibles en Latinoamérica y representan una opción terapéutica prometedora. Esta revisión compara ambos grupos farmacológicos desde diversos aspectos clave.
Descargas
Métricas
Citas
Díaz-Rubio M. Historical perspective of gastric acid inhibition. Drugs. 2005;65 Suppl 1:1-6. doi: 10.2165/00003495-200565001- 00002.
Shin JM, Vagin O, Munson K, Kidd M, Modlin IM, Sachs G. Molecular mechanisms in therapy of acid-related diseases. Cell Mol Life Sci. 2008;65(2):264-81. doi: 10.1007/s00018-007-7249-x.
Sachs G, Shin JM, Vagin O, Lambrecht N, Yakubov I, Munson K. The gastric H,K ATPase as a drug target: past, present, and future. J Clin Gastroenterol. 2007;41 Suppl 2(Suppl 2):S226- 242. doi: 10.1097/MCG.0b013e31803233b7.
Scarpignato C, Hunt RH. Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments. Curr Gastroenterol Rep. 2024;26(11):273-93. doi:10.1007/s11894-024-00939-3.
Strand DS, Kim D, Peura DA. 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver. 2017;11(1):27- 37. doi: 10.5009/gnl15502.
Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: protonpump inhibitor failure in gastro-oesophageal reflux disease- -where next? Aliment Pharmacol Ther. 2005;22(2):79-94. doi: 10.1111/j.1365-2036.2005.02531.x.
Chey WD, Mody RR, Wu EQ, Chen L, Kothari S, Persson B, et al. Treatment patterns and symptom control in patients with GERD: US community-based survey. Curr Med Res Opin. 2009;25(8):1869-78. doi: 10.1185/03007990903035745.
Maideen NMP. Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors. Chonnam Med J. 2023;59(2):115- 27. doi: 10.4068/cmj.2023.59.2.115.
Scarpignato C, Tolone S. Addressing long-term PPI safety. Dig Liver Dis. 2020;52(8):853-6. doi: 10.1016/j.dld.2020.05.025.
Scarpignato C, Hunt RH. Editorial: towards extended acid suppression--the search continues. Aliment Pharmacol Ther. 2015;42(8):1027-9. doi: 10.1111/apt.13384.
Helgadottir H, Bjornsson ES. Problems ssociated with Deprescribing of Proton Pump Inhibitors Int J Mol Sci . 2019;20(21):5469. doi: 10.3390/ijms20215469.
Cui G, Waldum HL. Physiological and clinical significance of enterochromaffin-like cell activation in the regulation of gastric acid secretion. World J Gastroenterol. 2007;13(4):493- 6. doi: 10.3748/wjg.v13.i4.493.
Geibel J. Gastric secretions en Yamada’s Textbook of Gastroenterology, Seventh Edition. En: Wang TC, Camilleri M, Lebwohl B, Lok AS, Sandborn WJ, Wang KK, et al. John Wiley & Sons Ltd.; 2022. p. 313-333.
Yao X, Forte JG. Cell biology of acid secretion by the parietal cell. Annu Rev Physiol. 2003;65:103-31. doi: 10.1146/annurev. physiol.65.072302.114200.
Song YH, Ma JY, Mardh S, Liu T, Sjostrand SE, Rask L, et al. Localization of a pernicious anaemia autoantibody epitope on the α-subunit of human H, K-adenosine triphosphatase. Scand. J. Gastroenterol. 1994;29 (2):122-127. doi: 10.3109/00365529409090449.
Ueno S, Takeda K, Noguchi S, Kawamura M. Significance of the beta-subunit in the biogenesis of Na+/K(+)-ATPase. Biosci Rep. 1997;17(2):173-88. doi: 10.1023/a:1027333529412.
Abe K, Tani K, Nishizawa T, Fujiyoshi Y. Inter-subunit interaction of gastric H+,K+-ATPase prevents reverse reaction of the transport cycle. EMBO J. 2009;28(11):1637-43. doi: 10.1038/ emboj.2009.102.
Dürr KL, Tavraz NN, Dempski RE, Bamberg E, Friedrich T. Functional Significance of E2 State Stabilization by Specific α/β-Subunit Interactions of Na,K- and H,K-ATPase*. J Biol Chem. 2009;284(6):3842-54. doi: 10.1074/jbc. M808101200.
Callaghan JM, Khan MA, Alderuccio F, van Driel IR, Gleeson PA, Toh BH. Alpha and beta subunits of the gastric H+/K(+)-ATPase are concordantly targeted by parietal cell autoantibodies associated with autoimmune gastritis. Autoimmunity. 1993;16(4):289-95. doi: 10.3109/08916939309014648.
Huang KZ, Weber HC. Potassium-competitive acid blockers and acid-related disorders. Curr Opin Endocrinol Diabetes Obes. 2024;31(3):107-14. doi: 10.1097/MED.00000000000000858.
Shin JM, Sachs G. Pharmacology of Proton Pump Inhibitors. Curr Gastroenterol Rep. 2008;10(6):528-34. doi: 10.1007/ s11894-008-0098-4.
Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006;23 Suppl 2:2-8. doi: 10.1111/j.1365-2036.2006.02943.x.
Wiesner A, Zwolińska-Wcisło M, Paśko P. Effect of Food and Dosing Regimen on Safety and Efficacy of Proton Pump Inhibitors Therapy-A Literature Review. Int J Environ Res Public Health. 2021;18(7):3527. doi: 10.3390/ijerph18073527.
Shin JM, Kim N. Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors. J Neurogastroenterol Motil. 2013;19(1):25-35. doi: 10.5056/jnm.2013.19.1.25.
Kagami T, Sahara S, Ichikawa H, Uotani T, Yamade M, Sugimoto M, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 2016;43(10):1048-59. doi: 10.1111/ apt.13588.
Dean L, Kane M. Omeprazole therapy and CYP2C19 genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical genetics summaries. National Center for Biotechnology Information (US); 2024.
Arévalo-Galvis A, Otero-Regino WA, Ovalle-Celis GN, Rodríguez-Gómez ER, Trespalacios-Rangel AA. Prevalence of CYP2C19 polymorphism in Bogotá, Colombia: The first report of allele *17. PLoS One. 2021;16(1):e0245401. doi: 10.1371/ journal.pone.0245401.
Howden CW. Immediate-Release Omeprazole/Sodium Bicarbonate. Gastroenterol Hepatol (N Y). 2006;2(5):386.
Castell D. Review of immediate-release omeprazole for the treatment of gastric acid-related disorders. Expert Opin Pharmacother. 2005;6(14):2501-10. doi: 10.1517/14656566.6.14.2501.
Small RE. Advances in Proton Pump Inhibitor Therapy: An Immediate-Release Formulation of Omeprazole [Internet]. Semantic Scholar; 2005 [citado 3 de enero de 2025]. Disponible en: https://www.semanticscholar.org/paper/Advances-inProton-Pump-Inhibitor-Therapy%3A-An-of-Small/59fd55b10 342abed9eba0556c63c91b78b929521
Kim D, Park MS, Yoo BW, Hong T, Park SJ, Kim CO. The safety, pharmacodynamics, and pharmacokinetics of immediaterelease formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male. Drug Des Devel Ther. 2019;13:3151-9. doi: 10.2147/DDDT. S212491.
Howden CW, Ballard ED, Koch FK, Gautille TC, Bagin RG. Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD. J Clin Gastroenterol. 2009;43(4):323-6. doi: 10.1097/MCG.0b013e31818a386e.
Santarus, Inc. [Internet]. Washington, D.C.; US Securities And Exchange Commission; 2007 [citado 3 de enero de 2025]. Disponible en: https://www.sec.gov/Archives/edgar/ data/1172480/000093639208000170/a38641e10vk.htm
Jing S, Zhu Y, Liu W, Yang K, Hu L, Deng D, et al. Pharmacokinetics and Pharmacodynamics of Esomeprazole/Sodium Bicarbonate Immediate-Release Capsules in Healthy Chinese Volunteers: A Cross-Over, Randomized Controlled Trial. Adv Ther. 2021;38(3):1660-76. doi: 10.1007/s12325-021-01644-7.
Park SH, Lee KN, Lee OY, Choi MG, Kim JH, Sung IK, et al. A Randomized, Double-Blind, Active-Control, Noninferiority, Multicenter, Phase 4 Study to Evaluate the Efficacy and Safety of Esomeprazole/Sodium Bicarbonate 20/800 mg in Patients with Nonerosive Gastroesophageal Reflux Disease. Gut Liver. 2023;17(2):226-33. doi: 10.5009/GNL220023.
Banerjee R, Reddy DN, Guda NM, Kalpala R, Mahurkar S, Darisetty S, et al. Oral buffered esomeprazole is superior to i.v. pantoprazole for rapid rise of intragastric pH: a wireless pH metry analysis. J Gastroenterol Hepatol. 2010;25(1):43-7. doi: 10.1111/j.1440-1746.2009.05994.x.
Audi S, Burrage DR, Lonsdale DO, Pontefract S, Coleman JJ, Hitchings AW, et al. The ‘top 100’ drugs and classes in England: an updated ‘starter formulary’ for trainee prescribers. Br J Clin Pharmacol. 2018;84(11):2562-71. doi: 10.1111/bcp.13709.
Galappatthy P, Ranasinghe P, Liyanage CK, Wijayabandara M, Warapitiya DS, Jayasekara D, et al. Core Prescribing Indicators and the Most Commonly Prescribed Medicines in a Tertiary Health Care Setting in a Developing Country. Adv Pharmacol Pharm Sci. 2021;2021:6625377. doi: 10.1155/2021/6625377.
World Health Organization. WHO Model Lists of Essential Medicines [Internet]. Ginebra: WHO; 2023 [citado 1 de enero de 2025]. Disponible en: https://www.who.int/groups/expertcommittee-on-selection-and-use-of-essential-medicines/ essential-medicines-lists
Fuentes AV, Pineda MD, Venkata KCN. Comprehension of Top 200 Prescribed Drugs in the US as a Resource for Pharmacy Teaching, Training and Practice. Pharmacy (Basel). 2018;6(2):43. doi: 10.3390/pharmacy6020043.
Shin JM, Munson K, Vagin O, Sachs G. The gastric HKATPase: structure, function, and inhibition. Pflugers Arch. 2009;457(3):609-22. doi: 10.1007/s00424-008-0495-4.
Inatomi N, Matsukawa J, Sakurai Y, Otake K. Potassiumcompetitive acid blockers: Advanced therapeutic option for acid-related diseases. Pharmacol Ther. 2016;168:12-22. doi: 10.1016/j.pharmthera.2016.08.001 .
Antequera CM, Orleck K, Jacob R, Kenneally A, Wright WL. Potassium-competitive acid blockers: rethinking acid suppression for gastroesophageal reflux disease and Helicobacter pylori. Postgrad Med. 2024;136(2):131-40. doi: 10.1080/00325481.2024.2320081.
Wong N, Reddy A, Patel A. Potassium-Competitive Acid Blockers: Present and Potential Utility in the Armamentarium for Acid Peptic Disorders. Gastroenterol Hepatol (N Y). 2022;18(12):693-700.
Garnock-Jones KP. Vonoprazan: first global approval. Drugs. 2015;75(4):439-43. doi: 10.1007/s40265-015-0368-z.
Tietto A, Faggin S, Scarpignato C, Savarino EV, Giron MC. Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Expert Opin Drug Metab Toxicol. 2025;21(1):53-68. doi: 10.1080/17425255.2024.2397433.
Hunt RH, Scarpignato C. Potent Acid Suppression with PPIs and P-CABs: What’s New? Curr Treat Options Gastroenterol. 2018;16(4):570-90. doi: 10.1007/s11938-018-0206-y.
Jenkins H, Sakurai Y, Nishimura A, Okamoto H, Hibberd M, Jenkins R, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41(7):636-48. doi: 10.1111/apt.13121.
Yamasaki H, Kawaguchi N, Nonaka M, Takahashi J, Morohashi A, Hirabayashi H, et al. In vitro metabolism of TAK438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017;47(12):1027-34. doi: 10.1080/00498254.2016.1203505.
Yang E, Kim S, Kim B, Kim B, Kim Y, Park SS, et al. Nighttime gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole. British Journal of Clinical Pharmacology. 2022;88(7):3288-96. doi: 10.1111/bcp.15268.
Karyampudi A, Ghoshal UC, Singh R, Verma A, Misra A, Saraswat VA. Esophageal Acidification During Nocturnal Acid-breakthrough with Ilaprazole Versus Omeprazole in Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2017;23(2):208-17. doi: 10.5056/jnm16087.
Nzeako UC, Murray JA. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy. Aliment Pharmacol Ther. 2002;16(7):1309- 16. doi: 10.1046/j.1365-2036.2002.t01-1-01281.x.
Katz PO, Anderson C, Khoury R, Castell DO. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther. 1998;12(12):1231-4. doi: 10.1046/j.1365-2036.1998.00419.x.
Ghoshal UC, Chourasia D, Tripathi S, Misra A, Singh K. Relationship of severity of gastroesophageal reflux disease with gastric acid secretory profile and esophageal acid exposure during nocturnal acid breakthrough: a study using 24-h dualchannel pH-metry. Scand J Gastroenterol. 2008;43(6):654-61. doi: 10.1080/00365520701864635.
Tutuian R, Castell DO. Nocturnal acid breakthrough - approach to management. MedGenMed. 2004;6(4):11.
Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol. 1998;93(5):763-7. doi: 10.1111/j.1572-0241.1998.221_a.x.
Han S, Choi HY, Kim YH, Choi S, Kim S, Nam JY, et al. Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study. Gut and Liver. 2023;17(1):92-9. doi: 10.5009/gnl220050.
Zou S, Ouyang M, Cheng Q, Shi X, Sun M. Acid-suppressive drugs: A systematic review and network meta-analysis of their nocturnal acid-inhibitory effect. Pharmacotherapy. 2024;44(2):171-83. doi: 10.1002/phar.2899.
Instituto Nacional de Vigilancia de Medicamentos y Alimentos. Sistema de Tramites en Linea - Consultas Publicas [Internet]. Lima: INVIMA [citado 25 de noviembre de 2024]. Disponible en: https://consultaregistro.invima.gov.co/Consultas/ consultas/consreg_encabcum.jsp
Antunes C, Aleem A, Curtis SA. Gastroesophageal Reflux Disease. En: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [citado 8 de enero de 2025]. Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK441938/
Savarino E, de Bortoli N, De Cassan C, Della Coletta M, Bartolo O, Furnari M, et al. The natural history of gastro-esophageal reflux disease: a comprehensive review. Dis Esophagus. 2017;30(2):1-9. doi: 10.1111/dote.12511.
Ashida K, Sakurai Y, Hori T, Kudou K, Nishimura A, Hiramatsu N, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43(2):240-51. doi: 10.1111/apt.13461.
Xiao Y, Zhang S, Dai N, Fei G, Goh KL, Chun HJ, et al. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut. 2020;69(2):224-30. doi: 10.1136/gutjnl-2019-318365.
Laine L, DeVault K, Katz P, Mitev S, Lowe J, Hunt B, et al. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial. Gastroenterology. 2023;164(1):61-71. doi: 10.1053/j. gastro.2022.09.041.
Simadibrata DM, Syam AF, Lee YY. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2022;37(12):2217-28. doi: 10.1111/jgh.16017.
Zhuang Q, Chen S, Zhou X, Jia X, Zhang M, Tan N, et al. Comparative Efficacy of P-CAB vs Proton Pump Inhibitors for Grade C/D Esophagitis: A Systematic Review and Network Meta-analysis. Am J Gastroenterol. 2024;119(5):803-13. doi: 10.14309/ajg.0000000000002714.
Simadibrata DM, Lesmana E, Fass R. Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: A systematic review with meta-analysis of randomized controlled trials. J Gastroenterol Hepatol. 2024;39(6):988-99. doi: 10.1111/jgh.16486.
Agago DE, Hanif N, Ajay Kumar AS, Arsalan M, Kaur Dhanjal M, Hanif L, et al. Comparison of Potassium-Competitive Acid Blockers and Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus. 16(7):e65141. doi: 10.7759/cureus.65141.
Simadibrata DM, Lesmana E, Pratama MIA, Sugiharta AJ, Winarizal AS, Lee YY, et al. A systematic review with metaanalysis: Efficacy and safety of potassium-competitive acid blocker compared with proton pump inhibitor in the maintenance of healed erosive esophagitis. JGH Open. 2024;8(3):e13053. doi: 10.1002/jgh3.13053.
Seo S, Jung HK, Gyawali CP, Lee HA, Lim HS, Jeong ES, et al. Treatment Response With Potassium-competitive Acid Blockers Based on Clinical Phenotypes of Gastroesophageal Reflux Disease: A Systematic Literature Review and Metaanalysis. J Neurogastroenterol Motil. 2024;30(3):259-71. doi: 10.5056/jnm24024.
Dean BB, Gano AD, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2(8):656-64. doi: 10.1016/s1542- 3565(04)00288-5.
Scarpignato C. Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end! Neurogastroenterol Motil. 2012;24(8):697-704. doi: 10.1111/j.1365-2982.2012.01977.x.
Gabbard S, Vijayvargiya S. Functional heartburn: An underrecognized cause of PPI-refractory symptoms. Cleve Clin J Med. 2019;86(12):799-806. doi: 10.3949/ccjm.86a.19006.
Kahrilas PJ, Boeckxstaens G, Smout AJPM. Management of the patient with incomplete response to PPI therapy. Best Pract Res Clin Gastroenterol. 2013;27(3):401-14. doi10.1016/j. bpg.2013.06.005.
Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Nonerosive reflux disease (NERD)--acid reflux and symptom patterns. Aliment Pharmacol Ther. 2003;17(4):537-45. doi: 10.1046/j.1365-2036.2003.01423.x.
Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Functional Esophageal Disorders. Gastroenterology. 2016;S0016-5085(16)00178-5. doi: 10.1053/j.gastro.2016.02.012.
Kinoshita Y, Sakurai Y, Shiino M, Kudou K, Nishimura A, Miyagi T, et al. Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. Curr Ther Res Clin Exp. 2016;81-82:1-7. doi: 10.1016/j.curtheres.2016.12.001.
Kinoshita Y, Sakurai Y, Takabayashi N, Kudou K, Araki T, Miyagi T, et al. Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study. Clin Transl Gastroenterol. 2019;10(11):e00101. doi: 10.14309/ctg.0000000000000101.
Fass R, Vaezi M, Sharma P, Yadlapati R, Hunt B, Harris T, et al. Randomised clinical trial: Efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease. Aliment Pharmacol Ther. 2023;58(10):1016-27. doi: 10.1111/ apt.17728.
Kim SH, Cho KB, Chun HJ, Lee SW, Kwon JG, Lee DH, et al. Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease. Aliment Pharmacol Ther. 2021;54(4):402-11. doi: 10.1111/apt.16477.
Hamada S, Ihara E, Ikeda H, Muta K, Ogino H, Chinen T, et al. Clinical Characterization of Vonoprazan-Refractory Gastroesophageal Reflux Disease. Digestion. 2021;102(2):197- 204. doi: 10.1159/000503340.
Lanas A, Chan FKL. Peptic ulcer disease. Lancet. 2017;390(10094):613-24. doi: 10.1016/S0140-6736(16)32404- 787.
Oh H, Kim KH, Lee KH, Yoo DW, Yoon IM. Efficacy of potassiumcompetitive acid blockers vs. proton pump inhibitors on gastric ulcers: Bayesian and frequentist network meta-analysis with cross-inference through a quality management system. Research Square; 2022. doi: 10.21203/rs.3.rs-2167246/v1.
Wang W xin, Li R jie, Li X fei. Efficacy and Safety of PotassiumCompetitive Acid Blockers vs Proton Pump Inhibitors for Peptic Ulcer Disease or Postprocedural Artificial Ulcers: A Systematic Review and Meta-analysis. Clin Transl Gastroenterol. 2024;15:e1. doi: 10.14309/ctg.0000000000000754.
Scott DR, Sachs G, Marcus EA. The role of acid inhibition in Helicobacter pylori eradication. F1000Res. 2016;5:F1000 Faculty Rev-1747. doi: 10.12688/f1000research.8598.1.
Sjöstedt S, Sagar M, Lindberg G, Wikström B, Nord CE, Seensalu R. Prolonged and profound acid inhibition is crucial in Helicobacter pylori treatment with a proton pump inhibitor combined with amoxicillin. Scand J Gastroenterol. 1998;33(1):39-43.
Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43(4):514-33. doi: 10.1111/apt.13497.
Kawai T, Takahashi S, Suzuki H, Sasaki H, Nagahara A, Asaoka D, et al. Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group). J Gastroenterol Hepatol. 2014;29 Suppl 4:29-32. doi: 10.1111/ jgh.12796.
Gong EJ, Yun SC, Jung HY, Lim H, Choi KS, Ahn JY, et al. MetaAnalysis of First-Line Triple Therapy for Helicobacter pylori Eradication in Korea: Is It Time to Change? J Korean Med Sci. 2014;29(5):704-13. doi: 10.3346/jkms.2014.29.5.704.
Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E, Araki T, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42(6):719-30. doi: 10.1111/apt.13325.
Nabeta H, Shinozaki S, Abe Y, Koyanagi R, Nakamichi T, Kobayashi Y, et al. A Potassium-Competitive Acid Blocker-Based Regimen as Second-Line Therapy Improves Helicobacter pylori Eradication. Digestion. 2020;101(3):332-8. doi: 10.1159/000499857.
Oh M, Lee H, Kim S, Kim B, Song GS, Shin JG, et al. Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects. Transl Clin Pharmacol. 2023;31(2):114-23. doi: 10.12793/tcp.2023.31.e11.
Cho JH. Bismuth add-on improves the efficacy of 2-week tegoprazan-based triple therapy for first-line Helicobacter pylori eradication: a real-world evidence study. Expert Rev Anti Infect Ther. 2024;22(9):793-9. doi: 10.1080/14787210.2024.2329251.
Jung YS, Kim S, Kim HY, Noh SJ, Park JH, Sohn CI, et al. Efficacy and Tolerability of 14-Day Tegoprazan- versus RabeprazoleBased Triple Therapy for Eradication of Helicobacter pylori: A Real-World Evidence Study. Gut and Liver. 2023;17(5):711-21. doi: 10.5009/gnl220218.
Lee JW, Kim N, Lee J, Jo SY, Lee DH. Efficacy of TegoprazanContaining Sequential Eradication Treatment Compared to Esomeprazole-Containing Sequential Eradication of Helicobacter pylori in South Korea, a Region With High Antimicrobial Resistance: A Prospective, Randomized, Single Tertiary Center Study. Helicobacter. 2024;29(5):e13143. doi: 10.1111/hel.13143.
Kong Q, Mirza IA, Zhang X, Song X, Li X, Zhang Q, et al. Fourteen-Day Tegoprazan-Amoxicillin Dual Therapy as the First-Line Treatment of Helicobacter pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial. Helicobacter. 2024;29(3):e13098. doi: 10.1111/ hel.13098.
Park CH, Park JH, Jung YS. Comparative Efficacy of Tegoprazan vs Esomeprazole/Sodium Bicarbonate for the Treatment of Helicobacter pylori Infection. Clin Transl Gastroenterol. 2023;14(11):e00632. doi: 10.14309/ctg.0000000000000632.
Kanu JE, Soldera J. Treatment of Helicobacter pylori with potassium competitive acid blockers: A systematic review and meta-analysis. World J Gastroenterol. 2024;30(9):1213-23. doi: 10.3748/wjg.v30.i9.1213.
Jiang Y, Zhang R, Fang Y, Zhao R, Fu Y, Ren P, et al. P-CAB versus PPI in the eradication of Helicobacter pylori: a systematic review and network meta-analysis. Therap Adv Gastroenterol. 2024;17:17562848241241223. doi: 10.1177/17562848241241223.
Li J, Shi H, Zhou F, Xie L, Lin R. The Efficacy and Safety of Regimens for Helicobacter pylori Eradication Treatment in China: A Systemic Review and Network Meta-Analysis. Journal of Clinical Gastroenterology. 2024;58(1):12-23. doi: 10.1097/MCG.0000000000001902.
Du RC, Hu YX, Ouyang Y, Ling LX, Xu JY, Sa R, et al. Vonoprazan and amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection: A systematic review and meta-analysis. Helicobacter. 2024;29(1):e13039. doi: 10.1111/hel.13039.
Shinozaki S, Kobayashi Y, Osawa H, Sakamoto H, Hayashi Y, Lefor AK, et al. Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis. Digestion. 2020;102(3):319-25. doi: 10.1159/000504939.
Wang Z, Wang F. Efficacy and safety comparison of Helicobacter pylori eradication between vonoprazan dual therapy versus triple therapy: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2022;15:17562848221125308. doi: 10.1177/17562848221125308 .
Chen PY, Tsai FP, Chen MJ, Yang HY, Wu MS, Liou JM. Vonoprazan-based versus proton pump inhibitor-based therapy in Helicobacter pylori eradication: an updated systematic review and meta-analysis of randomised trials. Gut. 2024;73(5):872-4. doi: 10.1136/gutjnl-2023-329826.
Targownik L. Discontinuing Long-Term PPI Therapy: Why, With Whom, and How? Am J Gastroenterol. 2018;113(4):519- 28. doi: 10.1038/ajg.2018.29.
Vaezi MF, Yang YX, Howden CW. Complications of Proton Pump Inhibitor Therapy. Gastroenterology. 2017;153(1):35- 48. doi: 10.1053/j.gastro.2017.04.047.
Savarino V, Dulbecco P, Savarino E. Are proton pump inhibitors really so dangerous? Dig Liver Dis. 2016;48(8):851- 9. doi: 10.1016/j.dld.2016.05.018.
Hill AB. The Environment and Disease: Association or Causation? Proc R Soc Med. 1965;58(5):295-300. doi: 10.1177/003591576505800503.
Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, et al. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology. 2019;157(3):682-691.e2. doi: 10.1053/j.gastro.2019.05.056.
Ahn N, Nolde M, Krause E, Güntner F, Günter A, Tauscher M, et al. Do proton pump inhibitors increase the risk of dementia? A systematic review, meta-analysis and bias analysis. Br J Clin Pharmacol. 2023;89(2):602-16. doi: 10.1111/bcp.15583.
Khan MA, Yuan Y, Iqbal U, Kamal S, Khan M, Khan Z, et al. No Association Linking Short-Term Proton Pump Inhibitor Use to Dementia: Systematic Review and Meta-analysis of Observational Studies. Am J Gastroenterol. 2020;115(6):671- 8. doi: 10.14309/ajg.0000000000000500.
Lee JK, Merchant SA, Schneider JL, Jensen CD, Fireman BH, Quesenberry CP, et al. Proton Pump Inhibitor Use and Risk of Gastric, Colorectal, Liver, and Pancreatic Cancers in a Community-Based Population. Am J Gastroenterol. 2020;115(5):706-15. doi: 10.14309/ajg.0000000000000591.
Mosholder AD, Hada M, Leishear K. Proton-Pump Inhibitors and Cardiovascular Adverse Events: A Meta-Analysis of Randomized Controlled Trials. Am J Gastroenterol. 2025;120(2):362-369. doi: 10.14309/ajg.0000000000003058.
Weir MR. Proton Pump Inhibitors and Kidney Disease: Fact or Fiction? Am J Nephrol. 2024;55(4):499-508. doi: 10.1159/000538755.
Rajan P, Iglay K, Rhodes T, Girman CJ, Bennett D, KalantarZadeh K. Risk of bias in non-randomized observational studies assessing the relationship between proton-pump inhibitors and adverse kidney outcomes: a systematic review. Therap Adv Gastroenterol. 2022;15:17562848221074183. doi: 10.1177/17562848221074183.
Moraes-Filho JPP, Domingues G, Chinzon D, Guedes JLS, Santos CY, Zaterka S. Vonoprazan in the management of gastric/peptic ulcers: a systematic review of safety data. Prz Gastroenterol. 2022;17(4):266-73. doi: 10.5114/ pg.2022.112777.
Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas PJ. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Alimentary Pharmacology & Therapeutics. 2015;42(6):649-63. doi: 10.1111/apt.13324.
Murugesan SVM, Varro A, Pritchard DM. Review article: strategies to determine whether hypergastrinaemia is due to Zollinger–Ellison syndrome rather than a more common benign cause. Alimentary Pharmacology & Therapeutics. 2009;29(10):1055-68. doi: 10.1111/j.1365-2036.2009.03976.x.
Hwang I, Lee S. Editorial: deja vu all over again - let the P-CAB wars begin. Authors’ reply. Aliment Pharmacol Ther. 2023;57(8):914-915. doi: 10.1111/apt.17444.
Haruma K, Kinoshita Y, Yao T, Kushima R, Akiyama J, Aoyama N, et al. Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis. BMC Gastroenterol. 2023;23(1):139. doi: 10.1186/s12876-023-02772-w.
Arai J, Hayakawa Y, Niikura R, Ihara S, Aoki T, Honda T, et al. Letter: Potassium-competitive acid blockers may increase the risk of gastric cancer after Helicobacter pylori eradication a retrospective multicentre-cohort analysis. Aliment Pharmacol Ther. 2023;57(10):1196-8. doi: 10.1111/apt.17461.
Waldum HL, Hauso Ø, Fossmark R. Letter: proton pump inhibitors, hypergastrinaemia and the risk of gastric neoplasia. Alimentary Pharmacology & Therapeutics. 2015;42(3):389-389. doi: 10.1111/apt.13282.
Joo MK, Park JJ, Chun HJ. Proton pump inhibitor: The dual role in gastric cancer. World J Gastroenterol. 2019;25(17):2058- 70. 10.3748/wjg.v25.i17.2058.
Arai J, Miyawaki A, Aoki T, Niikura R, Hayakawa Y, Fujiwara H, et al. Association Between Vonoprazan and the Risk of Gastric Cancer After Helicobacter pylori Eradication. Clin Gastroenterol Hepatol. 2024;22(6):1217-1225.e6. doi: 10.1016/j.cgh.2024.01.037.
Howden CW, Chey WD, Shah SC. Re-evaluating the Proposed Association Between Vonoprazan and Gastric Cancer Following Eradication of H. pylori Infection. Clin Gastroenterol Hepatol. 2025;23(1):182-3. doi: 10.1016/j.cgh.2024.04.015.
Grimes DA, Schulz KF. False alarms and pseudo-epidemics: the limitations of observational epidemiology. Obstet Gynecol. 2012;120(4):920-7. doi: 10.1097/AOG.0b013e31826af61a.
Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740-8. doi: 10.1136/gutjnl-2015-310376.
Seto CT, Jeraldo P, Orenstein R, Chia N, DiBaise JK. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome. 2014;2:42. doi: 10.1186/2049-2618-2-42.
Bouwknegt M, van Pelt W, Kubbinga ME, Weda M, Havelaar AH. Potential association between the recent increase in campylobacteriosis incidence in the Netherlands and proton-pump inhibitor use - an ecological study. Euro Surveill. 2014;19(32):20873. doi: 10.2807/1560-7917. es2014.19.32.20873.
Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, Yu Y, et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A. 2009;106(7):2365-70. doi: 10.1073/pnas.0812600106.
Amir I, Konikoff FM, Oppenheim M, Gophna U, Half EE. Gastric microbiota is altered in oesophagitis and Barrett’s oesophagus and further modified by proton pump inhibitors. Environ Microbiol. 2014;16(9):2905-14. doi: 10.1111/1462- 2920.12285.
Minalyan A, Gabrielyan L, Scott D, Jacobs J, Pisegna JR. The Gastric and Intestinal Microbiome: Role of Proton Pump Inhibitors. Curr Gastroenterol Rep. 2017;19(8):42. doi: 10.1007/s11894-017-0577-6.
Otsuka T, Sugimoto M, Inoue R, Ohno M, Ban H, Nishida A, et al. Influence of potassium-competitive acid blocker on the gut microbiome of Helicobacter pylori-negative healthy individuals. Gut. 2017;66(9):1723-5. doi: 10.1136/ gutjnl-2016-313312.
De Palma G, Nadal I, Medina M, Donat E, Ribes-Koninckx C, Calabuig M, et al. Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children. BMC Microbiol. 2010;10:63. doi: 10.1186/1471-2180-10-63.
Vogtmann E, Hua X, Zeller G, Sunagawa S, Voigt AY, Hercog R, et al. Colorectal Cancer and the Human Gut Microbiome: Reproducibility with Whole-Genome Shotgun Sequencing. PLoS One. 2016;11(5):e0155362. doi: 10.1371/journal. pone.0155362.
Salonen A, de Vos WM, Palva A. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology (Reading). 2010;156(Pt 11):3205-15. doi: 10.1099/mic.0.043257-0.
Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ. Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis. 2015;26:26191. doi: 10.3402/mehd.v26.26191.
Abuduwaili M, Boda T, Ito M, Takigawa H, Kotachi T, Matsuo T, et al. Serum Gastrin and Pepsinogen Levels after Administration of Acid Secretion Inhibitors for Ulcers due to Endoscopic Submucosal Dissection in Patients with Early Gastric Cancer. Gastroenterol Res Pract. 2022;2022:2830227. doi: 10.1155/2022/2830227.
Kubo K, Kimura N, Kato M. Potassium-competitive acid blocker-associated gastric mucosal lesions. Clin Endosc. 2024;57(4):417-23. doi: 10.5946/ce.2023.279.
Chey WD, Howden CW, Moss SF, Morgan DR, Greer KB, Grover S, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2024 Sep 1;119(9):1730-1753. doi: 10.14309/ajg.0000000000002968.
Asaoka D, Nagahara A, Hojo M, Matsumoto K, Ueyama H, Matsumoto K, et al. Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia. Biomed Rep. 2017;6(2):175-80. doi: 10.3892/ br.2016.828.
Huh CW, Youn YH, Jung DH, Cha RR, Kim YJ, Jung K, et al. Efficacy of Tegoprazan in Patients With Functional Dyspepsia: A Prospective, Multicenter, Single-arm Study. J Neurogastroenterol Motil. 2024;30(3):313-21. doi: 10.5056/ jnm23150.
Armstrong D. Potassium-Competitive Acid Blockers and Gastroesophageal Reflux Disease. Gastroenterol Hepatol (N Y). 2023;19(5):295-8.
Patel A, Laine L, Moayyedi P, Wu J. AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review. Gastroenterology. 2024;167(6):1228-38. doi: 10.1053/j.gastro.2024.06.038.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2025 Jose Augusto Urrego Díaz , William Otero, Hugo Cedrón, Hernando Marulanda, Alejandro Piscoya, Juan Sebastián Frías-Ordoñez, Lina Otero
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Revista de Gastroenterología del Perú by Sociedad Peruana de Gastroenterología del Perú is licensed under a Licencia Creative Commons Atribución 4.0 Internacional..
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
2022 